Survival effect of complete surgical resection of the primary tumor in patients with metastatic, high-risk neuroblastoma in a large Canadian cohort

被引:3
|
作者
Seemann, Natashia M. [1 ,2 ]
Erker, Craig [3 ]
Irwin, Meredith S. [4 ]
Lopushinsky, Steven R. [5 ]
Kulkarni, Ketan [3 ]
Fernandez, Conrad V. [3 ]
Romao, Rodrigo L. P. [1 ,6 ]
机构
[1] Dalhousie Univ, IWK Hlth Ctr, Dept Surg & Urol, Halifax, NS, Canada
[2] Western Univ, London Hlth Sci Ctr, Dept Surg, Childrens Hosp, London, ON, Canada
[3] Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Halifax, NS, Canada
[4] Univ Toronto, Hosp Sick Children, Dept Paediat, Toronto, ON, Canada
[5] Univ Calgary, Alberta Childrens Hosp, Dept Surg, Calgary, AB, Canada
[6] IWK Hlth Ctr, 5850-5980 Univ Ave POB 9700, Halifax, NS B3K 6R8, Canada
关键词
high-risk; metastatic; neuroblastoma; surgery; STAGE; 4; NEUROBLASTOMA; LOCAL-CONTROL; CLASSIFICATION-SYSTEM; SURGERY; IMPACT; AGE; CHILDREN; OLDER;
D O I
10.1002/pbc.30286
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeTo determine whether extent of surgical resection of the primary tumor correlates with survival in patients with International Neuroblastoma Staging System (INSS) stage 4, high-risk neuroblastoma. MethodsData were extracted for patients with newly diagnosed INSS stage 4, high-risk neuroblastoma between 2001 and 2019 from the national Cancer in Young People in Canada (CYPC) database. Complete resection was defined as gross total resection of primary tumor based on operative reports. Primary endpoints were 3 and 5-year event-free (EFS) and overall survival (OS). Survival analyses were completed using log-rank test and Cox proportional hazards regression including covariates of age, sex, decade of treatment (2001-2009 vs. 2010-2019), immunotherapy, and tandem stem cell transplant (SCT). ResultsOne-hundred and forty patients with complete surgical data were included. On univariate analysis, 3-year EFS and OS for patients that had complete versus incomplete resection was 71% (95% CI 57-80%) vs. 48% (36-60%) and 86% (75-93%) vs. 64% (51-74%), p = .008 and p = .002, respectively. 5-year EFS and OS for patients with complete resection also demonstrated significantly improved survival. On Cox Proportional Hazards models adjusted for age, immunotherapy, tandem SCT, and surgical resection, only complete resection was associated with statistically significant improved 3 year EFS and OS, HR = 0.48 (0.29-0.81; p = .006) and HR = 0.42 (0.24-0.73; p = .002). ConclusionsIn a large Canadian INSS stage 4 high-risk neuroblastoma cohort, complete surgical resection was associated with increased EFS and OS. Within the constraints of a retrospective study, these results suggest that the ability to achieve primary tumor complete resection in patients with metastatic high-risk disease is associated with improved survival.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Systemic Response Evaluated by Curie Score is not Correlated to the Complexity and Outcome of Primary Tumor Resection in High-Risk Neuroblastoma
    Hishiki, T.
    Kanamori, Y.
    Fujino, A.
    Watanabe, T.
    Tahara, K.
    Ohno, M.
    Takezoe, T.
    Kiyotani, C.
    Shioda, Y.
    Tomizawa, D.
    Kato, M.
    Terashima, K.
    Osumi, T.
    Miyazaki, O.
    Kitamura, M.
    Matsumoto, K.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S467 - S468
  • [22] Does Resection of the Primary Tumor Improve Survival in Patients With Metastatic Chondrosarcoma?
    Song, Kehan
    Song, Jian
    Chen, Feiyan
    Lin, Kaiyuan
    Ma, Xiaosheng
    Jiang, Jianyuan
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2019, 477 (03) : 573 - 583
  • [23] Little Effect of Etoposide on High-risk Neuroblastoma (HR-NB) Patients Survival
    Kiyotani, Chikako
    Shioda, Yoko
    Osumi, Tomoo
    Tomizawa, Daisuke
    Kato, Motohiro
    Terashima, Keita
    Matsumoto, Kimikazu
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S43 - S43
  • [24] Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma
    Lucas, John Thomas, Jr.
    Wakefield, Daniel Victor
    Doubrovin, Michael
    Li, Yimei
    Santiago, Teresa
    Federico, Sara Michele
    Merchant, Thomas E.
    Davidoff, Andrew M.
    Krasin, Matthew J.
    Shulkin, Barry L.
    Santana, Victor M.
    Furman, Wayne Lee
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 34 : 42 - 50
  • [25] Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study
    Adkins, ES
    Sawin, R
    Gerbing, RB
    London, WB
    Matthay, KK
    Haase, GM
    JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (06) : 931 - 936
  • [26] Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma
    Aschero, Rosario
    Castillo-Ecija, Helena
    Baulenas-Farres, Merce
    Resa-Pares, Claudia
    Jimenez-Cabaco, Ana
    Rodriguez, Eva
    Monterrubio, Carles
    Perez-Jaume, Sara
    Sunol, Mariona
    Chantada, Guillermo L.
    Lavarino, Cinzia
    Mora, Jaume
    Carcaboso, Angel M.
    PEDIATRIC BLOOD & CANCER, 2023, 70 (06)
  • [27] Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma
    Feng, Tingting
    Lv, Wangxia
    Yuan, Meiqin
    Shi, Zhong
    Zhong, Haijun
    Ling, Sunbin
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2019, 17 (1)
  • [28] Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma
    Tingting Feng
    Wangxia Lv
    Meiqin Yuan
    Zhong Shi
    Haijun Zhong
    Sunbin Ling
    World Journal of Surgical Oncology, 17
  • [29] The impact of gross total resection on local control and survival in high-risk neuroblastoma - Discussion
    Sandler, A
    LaQuaglia, MP
    Kiely, E
    Shochat, S
    JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (03) : 417 - 417
  • [30] Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
    Bao, Riyue
    Spranger, Stefani
    Hernandez, Kyle
    Zha, Yuanyuan
    Pytel, Peter
    Luke, Jason J.
    Gajewski, Thomas F.
    Volchenboum, Samuel L.
    Cohn, Susan L.
    Desai, Ami, V
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)